Oncology treatment electric field combined with lomoxin and tamoxetine to treat newly diagnosed glioblastoma

In the ef-14 trial for the newly diagnosed glioblastoma (ndGBM), TMZ therapy with tTFields significantly improved the overall survival rate of patientsIn the NOA-09/CeTeG trial, the combination of O6 methyloline DNA methyl transferase (MGMT) promoter methylation (MGMTm) ndGBM, Lomustine (LOmustine, CCNU) and tamoxamine combination therapy was superior to monomolymineTo date, there is no information on the combination of these two effective optionsLazaros Lazaridis, Department of Clinical Neuro-Oncology at the University of Essen Hospital, Duisburg-Essen, Germany, and others assess the combined use of these two treatments in MGMTm-ndGBM patients, published online december 2019 in Journal of Cancer Research and Oncologymethodologythe study screened patients in the Clinical Neuro-Oncology Department of Essen Hospital and the Clinical Neuro-Oncology Department of the University Hospital of Essen, Germany, between January 2017 and May 2019: histopathologically was diagnosed as MGMTm-ndGBM, and treated with TTFields and CCNU/TMZ after completing chemotherapyTwo-center retrospective analysis of 16 patientsThe parameters assessed, including safety results, common Toxicity Standards for Adverse Events (Common Toxicity Criteria for Adverse Events, CTCAE), Clinical Prognosis, and Therapeutic Compliancethe results of the resultsresults show that of the 16 patients, 7 patients had CTCAE 3 hematological adverse events, 4 cases of CTCAE s3 liver toxicity eventsSix patients were found to have mild to moderate skin toxicityAt the data cut-off, the patient's median progression life span (PFS) was 20 monthsThe utilization rate of TTFields showed high median compliance (83%)findingsthe study reveals for the first time that the combination of TTFields, Lomoxinandandande and tamoxetine is safe and feasible;